ImmunoPrecise Antibodies Ltd. (HYFT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ImmunoPrecise Antibodies Ltd. (HYFT) has a cash flow conversion efficiency ratio of -0.162x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.87 Million) by net assets ($17.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ImmunoPrecise Antibodies Ltd. (HYFT) total market value for the company's overall valuation and market capitalisation.
ImmunoPrecise Antibodies Ltd. - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how ImmunoPrecise Antibodies Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
ImmunoPrecise Antibodies Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImmunoPrecise Antibodies Ltd. ranked by their cash flow conversion efficiency. Explore ImmunoPrecise Antibodies Ltd. cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NEW STRATUS ENERGY
F:80N
|
0.011x |
|
Baoye Group Company Limited
F:BKG
|
0.006x |
|
Aplisens SA
WAR:APN
|
0.047x |
|
Cedergrenska AB
ST:CEDER
|
0.055x |
|
Savezone I C
KO:067830
|
0.013x |
|
Coheris SA
PA:COH
|
0.235x |
|
HAZER Group Ltd
AU:HZR
|
-0.222x |
|
Jia Wei Lifestyle Inc
TW:3557
|
0.048x |
Annual Cash Flow Conversion Efficiency for ImmunoPrecise Antibodies Ltd. (1997–2025)
The table below shows the annual cash flow conversion efficiency of ImmunoPrecise Antibodies Ltd. from 1997 to 2025. View ImmunoPrecise Antibodies Ltd. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $23.63 Million | $-6.41 Million | -0.271x | -116.75% |
| 2024-04-30 | $33.92 Million | $-4.25 Million | -0.125x | +63.52% |
| 2023-04-30 | $57.80 Million | $-19.83 Million | -0.343x | -159.84% |
| 2022-04-30 | $75.13 Million | $-9.92 Million | -0.132x | -1152.78% |
| 2021-04-30 | $56.92 Million | $-600.00K | -0.011x | +88.57% |
| 2020-04-30 | $15.09 Million | $-1.39 Million | -0.092x | +48.03% |
| 2019-04-30 | $18.07 Million | $-3.21 Million | -0.177x | +34.01% |
| 2018-04-30 | $12.70 Million | $-3.42 Million | -0.269x | -15.23% |
| 2017-04-30 | $3.09 Million | $-721.65K | -0.233x | -174.62% |
| 2016-04-30 | $908.26K | $284.09K | 0.313x | +80.64% |
| 2015-04-30 | $-208.52K | $-36.11K | 0.173x | -40.10% |
| 2014-04-30 | $-161.21K | $-46.60K | 0.289x | +1338.08% |
| 2013-04-30 | $-215.66K | $-4.33K | 0.020x | -98.18% |
| 2012-04-30 | $-119.89K | $-132.72K | 1.107x | +273.25% |
| 2011-04-30 | $125.81K | $-80.39K | -0.639x | -1011.31% |
| 2010-04-30 | $5.37 Million | $-308.49K | -0.057x | -150.56% |
| 2009-04-30 | $6.78 Million | $-155.68K | -0.023x | +77.54% |
| 2008-04-30 | $5.12 Million | $-523.45K | -0.102x | -85.67% |
| 2007-04-30 | $5.40 Million | $-297.31K | -0.055x | -94.49% |
| 2006-04-30 | $3.91 Million | $-110.59K | -0.028x | -45.53% |
| 2005-04-30 | $4.23 Million | $-82.20K | -0.019x | +84.83% |
| 2004-04-30 | $1.39 Million | $-178.69K | -0.128x | +30.59% |
| 2003-04-30 | $912.21K | $-168.38K | -0.185x | +54.45% |
| 2002-04-30 | $691.56K | $-280.23K | -0.405x | -1206.41% |
| 2001-04-30 | $262.24K | $-8.13K | -0.031x | +94.10% |
| 2000-04-30 | $396.53K | $-208.54K | -0.526x | -319.83% |
| 1999-04-30 | $1.62 Million | $-202.94K | -0.125x | -58.13% |
| 1998-04-30 | $2.86 Million | $-226.81K | -0.079x | -165.55% |
| 1997-04-30 | $3.63 Million | $-108.20K | -0.030x | -- |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more